Objective. Treg cells modulate immune responses and can suppress the development of autoimmune diseases. Tumor necrosis factor receptor II (TNFRII) has been recognized as a key receptor on these cells that facilitates expansion and stabilization of CD4+ Treg cells. The purpose of the present study was to investigate the therapeutic activity of a novel TNFRII agonist in experimental arthritis as well as the role of different Treg cell subsets.
Objective. Treg cells modulate immune responses and can suppress the development of autoimmune diseases. Tumor necrosis factor receptor II (TNFRII) has been recognized as a key receptor on these cells that facilitates expansion and stabilization of CD4+ Treg cells. The purpose of the present study was to investigate the therapeutic activity of a novel TNFRII agonist in experimental arthritis as well as the role of different Treg cell subsets.
Methods. A novel mouse TNFRII-selective fusion protein (EHD2-sc-mTNF R2 ) was generated by genetic engineering. Mouse T cells were incubated together with interleukin-2 and/or EHD2-sc-mTNF R2 , and the effects on Treg cells were analyzed by flow cytometry. Mice with collagen-induced arthritis (CIA) were treated with EHD2-scmTNF R2 or saline, and the therapeutic effects were monitored and characterized.
Results. Selective activation of TNFRII was found to expand both CD4+ and CD8+ Treg cells. Moreover, TNFRII activation elevated the number of CD4+CD25+ and CD8+CD25+ Treg cells and increased the number of FoxP3-expressing cells in CD8+, but not CD4+, Treg cells, indicating different mechanisms of TNFRII-induced expansion of diverse T cell subsets with suppressive activity. In the CIA model, we demonstrated that administration of the TNFRII agonist EHD2-sc-mTNF R2 led to the expansion of both CD4+ and CD8+ Treg cells in vivo and induced antiinflammatory responses that alleviated arthritis.
Conclusion. Our findings support the use of TNFRII-selective therapeutics as an effective approach to the treatment of arthritic disease and possibly other inflammatory and autoimmune diseases.
Tumor necrosis factor (TNF) is a multifunctional cytokine with pleiotropic functions. It is a master regulator of the immune system and a key player in the initiation and orchestration of inflammation and immunity. TNF is synthesized as a trimeric transmembrane protein (tmTNF) that can be proteolytically processed into soluble circulating TNF homotrimers (sTNF). Interestingly, sTNF and tmTNF differ in their capability to activate the 2 TNF receptors (TNFRs): TNFRI and TNFRII. Whereas TNFRI can be activated by both sTNF and tmTNF, TNFRII is dependent on tmTNF to be robustly activated (1) .
Deregulation of TNF expression and signaling can cause chronic inflammation, which may result in the development of autoimmune diseases and tissue damage (2) (3) (4) (5) (6) . Indeed, elevated TNF levels have been associated with several inflammatory diseases, such as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease; therapeutic agents that neutralize TNF are being successfully used to treat these diseases (7, 8) . Surprisingly, however, a clinical trial with an anti-TNF drug that blocks both sTNF and tmTNF in multiple sclerosis patients resulted in disease exacerbation and had to be stopped (9) . Moreover, the approved TNF inhibitors can cause severe side effects, including opportunistic infections, reactivation of tuberculosis, development of autoimmune disease, increased susceptibility to the development of lymphoma, and demyelinating diseases (3, 7, 8) . These side effects most likely depend on the different biologic actions of TNF that are mediated via its 2 receptors.
Recent research has revealed that the TNF receptors induce dichotomous biologic responses. Whereas TNFRI signaling promotes inflammation and tissue degeneration, TNFRII contributes to immune suppression as well as tissue homeostasis and regeneration (3, 10) . Therefore, next-generation therapeutic approaches targeting the TNF system were developed, including blocking of sTNF-TNFRI interaction or signaling (11) (12) (13) (14) (15) (16) and selective activation of TNFRII (16) (17) (18) .
The immunosuppressive activity mediated through TNFRII is of particular interest for potential therapeutic application in autoimmune diseases. The immunosuppressive properties of TNFRII are mainly mediated by the expansion and stabilization of Treg cells (19) (20) (21) (22) , a highly specialized subpopulation of T cells that function to suppress immune responses. According to the prevailing view, Treg cells regulate the self tolerance of the immune system and help to prevent the development of autoimmune diseases. In addition to CD4+ Treg cells, additional T cell subpopulations with regulatory activity exist (i.e., CD8+ Treg cells). Similar to CD4+ Treg cells, the most potent suppressors are characterized by the expression of TNFRII (23, 24) . Interestingly, both CD4+ and CD8+ Treg cells have been shown to ameliorate experimental arthritis (25, 26) .
To scrutinize the impact of selective activation of TNFRII on Treg cell expansion and function, we recently developed a hexavalent human TNFRII-specific TNF, EHD2-scTNF R2 (16) , that mimics the activity of tmTNF. We have also generated the murine ortholog and describe herein that EHD2-sc-mTNF R2 selectively expanded CD4+ and CD8+ Treg cells in vitro and in vivo. Moreover, in the type II collagen-induced arthritis (CIA) model, EHD2-sc-mTNF R2 mediated antiinflammatory responses and alleviated arthritic disease. Our results suggest that therapeutic strategies based on the concept of TNFRII-dependent expansion of CD4+ and/or CD8+ Treg cells may represent a new and effective approach to the treatment of arthritic diseases and potentially various other inflammatory diseases.
MATERIALS AND METHODS
Biologic materials. Blood was obtained from volunteer donors who gave their informed consent. Blood withdrawal was carried out in accordance with relevant guidelines and regulations, and all experimental protocols were approved by the Ethik-Kommission Universit€ atsklinikum T€ ubingen (project no. 283/2014B02).
Animals. DBA/1 mice were purchased from Charles River. Animal care and all experiments performed were in accordance with federal and European guidelines and were approved by Regierungspr€ asidium Stuttgart (AZ 35-9185.81/0398).
Mouse T cell isolation, culture, and flow cytometry. Spleens were dissociated through a 40-lm cell strainer and collected in 10 ml of magnetic-activated cell sorter (MACS) buffer (phosphate buffered saline [PBS], 0.5% bovine serum albumin [BSA] , and 2 mM EDTA). Splenocytes were centrifuged at 300g for 5 minutes and washed once with 10 ml of MACS buffer. Then CD3+, CD4+, or CD8+ T cells were isolated using a FACSAria III cell sorter (BD). Purified T cells were activated using plate-bound anti-CD3 (5 lg/ml for 6 hours at 4°C) in combination with soluble anti-CD28 (2 lg/ml) and cultivated for 4 days in 96-well (U-form) plates in the presence of interleukin-2 (IL-2), EHD2-sc-mTNF R2 , or a combination of the 2 cytokines in TexMACS medium (Miltenyi Biotec). Expression of different T cell markers was then determined by flow cytometry according to manufacturer's instructions (Miltenyi Biotec). Data were acquired using a MACSQuant Analyzer 10 (Miltenyi Biotec) and analyzed with FlowJo software.
Suppression assay. Spleens were dissociated through a 40-lm cell strainer and collected in 10 ml of MACS buffer. Splenocytes were centrifuged (300g for 5 minutes) and washed once with 10 ml of MACS buffer. Then, CD4+ or CD8+ T cells were isolated by magnetic separation (Miltenyi Biotec). Purified T cells were activated using plate-bound anti-CD3 (5 lg/ml for 6 hours at 4°C) in combination with soluble anti-CD28 (2 lg/ml) and cultivated for 4 days in 96-well (U-form) plates in the presence of IL-2 (100 units/ml), EHD2-sc-mTNF R2 , or a combination of the 2 cytokines. Expanded Treg cells were then enriched using a Treg cell isolation kit (Miltenyi Biotec) and cultivated together with CD4+CD25-T responder cells at different ratios in the presence of CD3/CD28-coated MACSiBeads. After 16 hours, cells were incubated with bromodeoxyuridine (BrdU) for an additional 16 hours to label proliferating T responder cells. Proliferation of T responder cells was analyzed using a BrdU Cell Proliferation Assay kit (Cell Signaling Technologies) according to manufacturer's instructions. Absorbance at 450 nm was measured, and BrdU incorporation was determined using GraphPad Prism software.
Human T cell isolation, culture, and flow cytometry. Blood obtained from volunteer donors and peripheral blood mononuclear cells (PBMCs) were isolated by density-gradient centrifugation. Therefore, blood was diluted 1:2 with RPMI 1640 medium. Then, 30 ml of diluted blood was layered over 10 ml of Histopaque 1077 (Sigma-Aldrich) and centrifuged for 20 minutes at 800g. The interphase, including PBMCs, was then removed and washed with 30 ml of RPMI 1640 and centrifuged at 300g for 5 minutes. To remove platelets, cells were resuspended in 40 ml of RPMI 1640 and centrifuged for 5 minutes at 200g. CD4+ or CD8+ T cells were isolated by magnetic separation, using a CD4+ or CD8+ T cell isolation kit, according to the manufacturer's instructions (Miltenyi Biotec).
Purified T cells were resuspended in X-Vivo 15 medium (Lonza) and plated in anti-CD3-coated (1 lg/ml for 6 hours at 4°C) 96-well (U-form) plates for T cell activation. Cells were then cultivated for 4 days in the presence of IL-2 (30 units/ml) and the oligomerized fusion proteins. The expression of CD4, CD8, CD25, and FoxP3 was determined by flow cytometry according to the manufacturer's instructions (Miltenyi Biotec). Data were acquired using a MACSQuant Analyzer 10 and analyzed with FlowJo software.
Induction and assessment of CIA. CIA was induced as previously described (27) . Briefly, male DBA/1 mice were immunized at 12 weeks of age by subcutaneous injection at the base of the tail with 100 lg of bovine type II collagen (Chondrex) in Freund's complete adjuvant (Sigma). Treatment of mice with 10 mg/kg of EHD2-sc-mTNF R2 was started either 4 days after immunization (early treatment) or when the mice had developed signs of arthritis (late treatment). Mice were then treated by intraperitoneal injection twice a week. Clinical severity of the arthritis was monitored throughout. Clinical changes were scored on a scale of 0-4, where 0 represents no evidence of erythema and swelling, 1 represents erythema and mild swelling confined to the tarsal joints or ankle joint, 2 represents erythema and mild swelling extending from the ankle to the tarsal joints, 3 represents erythema and moderate swelling extending from the ankle to metatarsal joints, and 4 represents erythema and severe swelling encompassing the ankle, foot, and digits, or ankylosis of the limb (28) .
Preparation of paws and immunofluorescence microscopy. Samples were fixed in 3.7% formalin solution for 24 hours and were then decalcified for 2-4 weeks in a 14% EDTA solution (Sigma) buffered to pH 7.2, with changes of the decalcifying solution twice a week. After dehydration in a solution of PBS containing 20% sucrose, samples were then embedded in Tissue-Tek Figure 1 . Bioactivity of the mouse tumor necrosis factor receptor type II (TNFRII) agonist EHD2-sc-mTNF R2 . A, Schematic representation of EHD2-sc-mTNF R2 . B, Coomassie blue staining and immunoblotting with anti-TNF of EHD2-sc-mTNF R2 under reducing (with 2-mercaptoethanol) and nonreducing (without 2-mercaptoethanol) conditions. C, Size-exclusion chromatography of sc-mTNF R2 and EHD2-sc-mTNF R2 . D, Binding of sc-mTNF R2 (triangles), EHD2-sc-mTNF R2 (diamonds), and recombinant soluble mouse TNF (squares) to mouse TNFRI (mTNFRI) and mTNFRII, as determined by enzyme-linked immunosorbent assay (ELISA). Values are the mean AE SEM of 3 mice per group. E, Number of thymocytes after 3 days of cultivation of primary thymocytes in the presence of sc-mTNF R2 (triangles) or EHD2-sc-mTNF R2 (diamonds). Cell numbers were determined by measuring the metabolic activity using the MTT assay. Values are the mean AE SEM of 5 mice per group. F, Serum levels of EHD2-sc-mTNF R2 in mice injected intraperitoneally with EHD2-sc-mTNF R2 (10 mg/kg of body weight). Blood samples were taken, and serum was prepared and analyzed by ELISA. Values are the mean AE SEM of 6 mice per group. G, Percentage of CD4+FoxP3+ Treg cells in mice injected with saline or EHD2-sc-mTNF R2 , as determined by flow cytometry. Three days after the initial injection, mice received a second injection, and after 1 week, spleens were extracted for analysis. Shown are representative scatterplots (left) and combined data (right) from 3 independent experiments. Values are the mean AE SEM. * = P < 0.05; **** = P < 0.0001. Color figure can be viewed in the online issue, which is available at http://onlinelibrary. wiley.com/doi/10.1002/art.40413/abstract.
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FISCHER ET AL (Sakura Finetek), quick-frozen floating on liquid nitrogen, and stored at -20°C until further investigation. Cryosections measuring 10-12 lm thick were obtained using a cryostat (Leica Biosystems). After immunofluorescence staining, sections were analyzed using widefield fluorescence microscopy with a 209 objective lens (AxioObserver; Carl Zeiss). The number of CD4+ or CD8+ cells was quantified using ImageJ Fiji (29, 30) . Histologic scoring. After air-drying for 1 hour, the tissue sections were rehydrated in PBS for 20 minutes. After hematoxylin and eosin staining of the sections, the overall structure of the joints was evaluated by microscopy. A histologic score was determined as the total score for the following analyses: erosions of bone (0-4 points), degradation of cartilage (0-4 points), inflammation of synovial tissue (0-4 points) and adjacent joint tissue (0-4 points), and infiltration of immune cells into the joint cavity (0-4 points). The maximum possible score was 20 points. A scientist who was blinded with regard to the experimental group (HS) performed the histologic scoring.
Flow cytometry of spleen cells. Spleens were dissociated through a 40-lm cell strainer and collected in 10 ml of MACS buffer. Splenocytes were harvested by centrifugation (300g for 5 minutes) and washed once with 10 ml MACS buffer. The expression of different immune cell markers was investigated by flow cytometry according to the manufacturer's instructions (Miltenyi Biotec). Data were acquired using a MACSQuant Analyzer 10 and analyzed with FlowJo software.
Other methods used in these studies are described in detail in the Supplementary Methods section (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.40413/abstract).
Statistical analysis. Data are presented as the mean AE SEM of n independent experiments. Statistical analyses were performed using Student's t-test or analysis of variance, followed by a post hoc Tukey's range test. P values less than 0.05 were considered significant.
RESULTS
Generation and characterization of a mouse TNFRII-selective agonist. We recently introduced a fully human TNFRII-selective TNF mutein (EHD2-scTNF R2 ) that protected cholinergic neurons from degeneration in vivo (16) . Since human TNF does not activate mouse TNFRII (31) (32) (33) , the use of this fusion protein is restricted to in vitro studies with human cells or in vivo mouse studies with TNFRII-humanized mice (16) . For use in nonhumanized mice, we genetically engineered a mouse TNFRII-specific variant of EHD2-scTNF R2 (EHD2-scmTNF R2 ). EHD2-sc-mTNF R2 is composed of a covalently stabilized TNFRII-selective (D221N/A223R) (17,34) singlechain mouse TNF (sc-mTNF R2 ; amino acids 91-235) fused to the EH domain-containing protein 2 (EHD2) dimerization domain derived from the heavy-chain domain C H 2 of IgE (35), constituting a disulfide-bonded dimer that is, with respect to TNFRII interaction sites, a hexavalent molecule ( Figure 1A) .
The purity of the recombinant protein was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Coomassie blue staining or immunoblotting ( Figure 1B) . Under reducing conditions, the TNF mutein exhibited an apparent molecular mass of~70 kd, matching the calculated molecular mass of 66.6 kd. Under nonreducing conditions, the expected dimer of~130 kd was observed ( Figure 1B) . The oligomerization state of EHD2-sc-mTNF R2 was further confirmed by size-exclusion chromatography (Figure 1C) , where the fusion protein eluted as a single major peak, indicating the high purity of the fusion proteins.
TNFR selectivity and affinity to TNFRII were confirmed by binding studies using immobilized mouse TNFRI-Fc and TNFRII-Fc fusion proteins ( Figure 1D ). In contrast to recombinant sTNF, no binding of the TNFRII-selective TNF muteins to TNFRI was observed at any concentration tested ( Figure 1D ). However, both scmTNF R2 and EHD2-sc-mTNF R2 bound to TNFRII with 50% effective concentration (EC 50 Figure 1B) .
The superior bioactivity of EHD2-sc-mTNF R2 was demonstrated using TNFRII-induced proliferation of mouse thymocytes. Both sc-mTNF R2 and EHD2-scmTNF R2 induced the proliferation of isolated thymocytes, but EHD2-sc-mTNF R2 showed highly superior activity, as demonstrated by its 10-fold higher bioactivity (EC 50 for scmTNF R2 versus EHD2-sc-mTNF R2 0.8 nM versus 0.08 nM) ( Figure 1E ). The in vivo half-life of EHD2-scmTNF R2 was investigated after intraperitoneal injection into DBA/1 mice with the use of a His-tag-specific enzymelinked immunosorbent assay. EHD2-sc-mTNF R2 showed a half-life of 16.5 hours ( Figure 1F ). Next, we determined the in vivo bioactivity of EHD2-sc-mTNF R2 by measuring CD4+ Treg cell expansion after intraperitoneal administration. An EHD2-sc-mTNF R2 concentration of 1 mg/kg of body weight led to a significant 50% expansion of Treg cells, whereas a concentration of 10 mg/kg of body weight increased the number of Treg cells~3-fold ( Figure 1G) .
TNFRII signaling-induced expansion of CD4+ and CD8+ Treg cells. TNFRII is expressed on CD4+ and CD8+ Treg cells (20, 23, 24, 36) and contributes to the expansion and stabilization of CD4+ Treg cells (19) (20) (21) (22) . We therefore investigated the impact of EHD2-scmTNF R2 on CD4+ and CD8+ Treg cell expansion. Purified CD4+ or CD8+ mouse T cells were activated using anti- or TNFRII -/-mice, we confirmed that EHD2-sc-mTNF R2 selectively activates TNFRII, but not TNFRI. Whereas CD4+ and CD8+ Treg cells were expanded in mice lacking TNFRI, no effect of EHD2-sc-mTNF R2 was observed in TNFRII -/-mice ( Figure 2C ). (Figure 2E) . In contrast, EHD2-sc-mTNF R2 induced a more robust proliferative response compared to IL-2 expansion in only CD8+ FoxP3+ Treg cells ( Figure 2E) .
Proliferation of regulatory T cells was analyzed by measuring BrdU incorporation (Figures 2D and E). Both in the CD4+ and the CD8+ T cell populations, the majority of BrdU+ cells were FoxP3+ Treg cells, whereas FoxP3-conventional T cells did not incorporate BrdU. Proliferation of FoxP3+ Treg cells was mainly induced by IL-2 in the population of CD4+ T cells, as indicated by the similar percentages of BrdU+FoxP3+ Treg cells
Interestingly, EHD2-sc-mTNF R2 had differential effects on the number of CD4+ and CD8+ Treg cells expressing CD25 and FoxP3. Whereas upon IL-2 costimulation, EHD2-sc-mTNF R2 significantly increased the number of CD25+ CD4+ T cells, no elevation of CD25+ cells was observed for the CD8+ T cells ( Figure 3A and Supplementary Figure 3A , available at http://onlinelibrary.wiley. com/doi/10.1002/art.40413/abstract). In contrast, in the presence of IL-2, EHD2-sc-mTNF R2 significantly increased the number of FoxP3+ CD8+ T cells, whereas no change was observed for the CD4+ T cells ( Figure 3B Next, we investigated whether selective activation of TNFRII affected the suppressive activity of Treg cells. We therefore expanded Treg cells in CD4+ ( Figure 3C ) or CD8+ ( Figure 3D ) T cell populations using IL-2 either alone or in combination with EHD2-sc-mTNF R2 . After 4 days, Treg cells were isolated by magnetic cell separation and cultivated together with CD4+CD25-T responder cells in different ratios in the presence of CD3/CD28-coated MACSiBeads for polyclonal T cell activation. Suppressive activity was investigated by quantifying BrdU incorporation by T responder cells. The presence of Treg cells suppressed the proliferation of T responder cells. However, no differences in the suppressive activity between IL-2 and IL-2/ EHD2-sc-mTNF R2 -expanded CD4+ or CD8+ Treg cells was observed, indicating that TNFRII mainly triggers clonal expansion of Treg cells, but does not alter the suppressive activity of the expanded Treg cells.
We then made use of the human TNFRII-specific TNF mutein EHD2-scTNF R2 (16) to investigate TNFRIIinduced expansion of human Treg cells. CD4+ or CD8+ T cells were isolated from human blood, cultivated in IL-2-containing medium with or without EHD2-scTNF R2 , and after 4 days, the proportion of CD25+FoxP3+ Treg cells was quantified by flow cytometry. Similar to the results with mouse T cells, both CD4+ and CD8+ human Treg cells were most efficiently expanded in the presence of EHD2-scTNF R2 (Figures 3E and F) .
EHD2-sc-mTNF R2 alleviation of experimental arthritis. Due to their immunosuppressive and antiinflammatory roles, Treg cell expansion and activation are considered a potential therapeutic strategy in a variety of autoimmune and inflammatory diseases. Indeed, there is increasing evidence of a beneficial role of Treg cells in different animal models of inflammatory diseases (38) (39) (40) . In particular, Treg cells were shown to alleviate the arthritic disease in experimental arthritis (26, 38) , a rodent model of RA, a human autoimmune disorder characterized primarily by joint inflammation and erosion (41) . Experimental arthritis shares several similarities with human RA, including breach of self-tolerance, generation of autoantibodies, inflammatory changes in multiple joints, and erosion of articular bone and cartilage, accompanied by pannus formation (42) .
To investigate the potential therapeutic activity of the TNFRII agonist EHD2-sc-mTNF R2 in experimental arthritis, we used the CIA model in DBA/1 mice, treating them at different times after immunization with the TNFRII agonist EHD2-sc-mTNF R2 (10 mg/kg) or saline and monitoring the disease course over time. Interestingly, if treatment was started before the onset of an arthritic phenotype (early treatment), mice were significantly protected from experimental arthritis. If, in contrast, treatment was started only after the onset of phenotypically apparent arthritis (late treatment), it was 728 FISCHER ET AL Figure 4 . Alleviation of experimental arthritis following treatment with tumor necrosis factor receptor type II agonist. Mice were immunized with type II collagen in Freund's complete adjuvant. Intraperitoneal treatment with EHD2-sc-mTNF R2 (10 mg/kg of body weight) or saline (n = 21 mice) was started 4 days after immunization (early treatment; n = 18 mice) or on the day of arthritis onset (late treatment; n = 6 mice) and was repeated twice weekly. A and B, Arthritis scores (A) and numbers of arthritic paws (B) monitored over a 10-day period after the onset of arthritis. Values are the mean AE SEM. **** = P < 0.0001. C, Arthritis scores, numbers of arthritic paws, and mean scores per arthritic limb (score of ≥1) 10 days after the onset of arthritis in the 3 experimental groups. * = P < 0.05; ** = P < 0.01. D, Day of arthritis onset, defined as the first day after immunization on which there were arthritis symptoms, in mice receiving saline or EHD2-sc-mTNF R2 . E, Hematoxylin and eosin staining of paw sections (10-12 lm) from a saline-treated mouse and an EHD2-sc-mTNF R2 -treated mouse 10 days after the onset of arthritis. Arrows indicate infiltration of cells into the joint space, synovial tissue, and surrounding tissue; arrowheads indicate bone erosion and chondral destruction. F, Histologic arthritis scores in saline-treated and EHD2-sc-mTNF R2 -treated mice (n = 8 mice per group). ** = P < 0.01. Data in C, D, and F are shown as box plots. Each box represents the 25th to 75th percentiles. Lines inside the boxes represent the median. Whiskers represent the 10th and 90th percentiles. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40413/abstract. not therapeutic (Figures 4A-C) . While early treatment did not affect the day of onset of an arthritis phenotype, it strongly reduced the number of arthritic paws ( Figures 4B  and D) . Due to the therapeutic activity observed with the early treatment, this protocol was used in the following experiments. A detailed histologic analysis of the joints was performed to determine the histologic score, which consisted of bone erosion, degradation of cartilage, inflammation of synovial tissue and adjacent joint tissue, as well as infiltration of immune cells into the joint cavity. For all of these parameters, we observed reduced damage in EHD2-sc-mTNF R2 -treated mice as compared to saline-treated controls, resulting in a significantly reduced histologic score (Figures 4E and F) .
Interestingly, 3 weeks after immunization in EHD2-sc-mTNF R2 -treated mice, but before the onset of arthritis, the number of splenic CD3+ T cells (mainly represented by CD4+ T cells) was reduced, whereas the proportions of both CD4+ and CD8+ Treg cells were increased (Figure 5A ), compared to the numbers in saline-treated controls. No changes in the number of CD8+ cytotoxic T cells, B cells, monocytes, neutrophils, or dendritic cells were observed ( Figure 5A ). In contrast, 10 days after arthritis onset, no significant differences in the number of splenic T cells or the numbers of CD4+ and CD8+ Treg cells in particular were observed ( Figure 5B ). At the same time point, however, the number of CD4+ T helper cells and CD8+ cytotoxic Tcells detectable in the paws of arthritic mice was significantly reduced in EHD2-sc-mTNF R2 -treated mice compared to saline-treated controls. In addition, the numbers of paw-infiltrating CD68+ macrophages were significantly reduced in EHD2-sc-mTNF R2 -treated mice compared to saline-treated mice, indicating a reduction in joint inflammation (Figures 6A and B) .
Consistent with the TNFRII agonist-induced upregulation of the number of Treg cells, elevated levels of the key antiinflammatory cytokine IL-10 were found in the blood of EHD2-sc-mTNF R2 -treated mice 3 weeks after immunization ( Figure 6C ). In contrast, no differences in the levels of the inflammatory markers C-reactive protein, interferon-c, and IL-6 were noted between saline-treated and EHD2-sc-mTNF R2 -treated mice (Figure 6C) . Similar results were observed 10 days after the onset of arthritis, with IL-10 levels still found to be elevated ( Figure 6D ).
DISCUSSION
CD4+FoxP3+ Treg cells play an essential role in the maintenance of immunologic homeostasis and in the prevention of autoimmune disorders (43) . Over the last few years, TNFRII has been recognized to be a key receptor on CD4+ Treg cells. The expression of TNFRII not only defines the most suppressive Treg cells, but the activation of TNFRII also expands and stabilizes Treg cells in an inflammatory environment (19) (20) (21) 36, 44) . Aside from CD4+ Treg cells, other T cell subsets with immunosuppressive activity exist. In particular, the suppressive effects of CD8+ Treg cells on normal and pathologic immune responses have been known for decades. However, unlike CD4+ Treg cells, few CD8+ T cells with suppressive activity exist, and less is known about this Treg cell subpopulation. Similar to CD4+ Treg cells, TNFRII is expressed on CD8+ Treg cells, and TNFRII expression identifies the most potent CD8+ Treg cells (23, 24) .
To investigate the effect of selective TNFRII activation on both CD4+ and CD8+ Treg cells, we genetically engineered a novel mouse TNFRII agonist, EHD2-scmTNF R2 , and showed that this fusion protein is capable of expanding both mouse and human CD4+ and CD8+ Treg cells. As expected, the in vitro expansion of both CD4+ and CD8+ Treg cells was strongly increased in the presence of the T cell growth factor IL-2, which was previously shown to be essential for the generation of clinically useful human CD4+ (37) and CD8+ (24) Treg cells. Our data show that TNFRII and IL-2 signaling synergistically induce the expansion of Treg cells in vitro. Unexpectedly, the TNFRII agonist is functional on its own in vivo, indicating clear therapeutic potential of TNFRII agonists by themselves. An obvious explanation for this observation could be that, in vivo, endogenously produced IL-2 are sufficient for proper activation of IL-2-responsive cells and, thus, could render IL-2 treatments superfluous.
Interestingly, 2 injections of EHD2-sc-mTNF R2 induced expansion of CD4+ Treg cells ( Figure 1G ), but not CD8+ Treg cells (data not shown), in naive mice. In contrast, in mice with CIA, twice weekly injection of EHD2-sc-mTNF R2 efficiently induced expansion of both CD4+ and CD8+ Treg cells ( Figure 5A ). This indicates that CD8+ Treg cells might need an inflammatory environment for TNFRII-dependent in vivo expansion to occur. It was recently shown that in naive mice, repeated injection of a TNFRII agonist is necessary for expansion of CD4+ Treg cells, whereas in mice with chronic inflammation, a single injection expands CD4+ Treg cells (45) . Therefore, it might be possible that additional injections of the TNFRII agonist in naive mice might also lead to increased CD8+ Treg expansion.
The TNFRII agonist mainly induced expansion of both CD4+ and CD8+ Treg subpopulations, whereas at the single-cell level, the suppressive potential was not altered. This is consistent with a recent report on TNFRIIselective expansion of CD4+ Treg cells (17) . Importantly, Figure 6 . Induction of antiinflammatory responses following treatment with tumor necrosis factor receptor type II agonist in mice with experimental arthritis. A, Representative sections (10-12 lm) of paws obtained 10 days after the onset of arthritis in mice treated with saline or with EHD2-sc-mTNF R2 . Staining with CD4, CD8, or CD68 indicates T cell and macrophage infiltration. Hoechst 33258 staining indicates nuclei. B, Quantification of the numbers of infiltrating CD4+ and CD8+ T cells and CD68+ macrophages. Values are the mean AE SEM of 7 mice per group for CD4+ and CD8+ cells and 3 mice per group for CD68+ cells. C and D, Levels of the indicated inflammatory and antiinflammatory markers, as determined by enzyme-linked immunosorbent assay. Whole blood samples were taken 3 weeks after immunization, but before the onset of arthritis (C), or 10 days after the onset of arthritis (D). Values are the mean AE SEM of 18 saline-treated mice and 17 EHD2-sc-mTNF R2 -treated mice. * = P < 0.05; ** = P < 0.01. CRP = C-reactive protein; NS = not significant; IFNc = interferon-c; IL-6 = interleukin-6.
TNFRII agonist-mediated expansion of Treg cells is not restricted to mouse immune cells, as similar effects were observed for both CD4+ and CD8+ human Treg cells, indicating the translational potential of TNFRII-induced Treg cell expansion.
Interestingly, TNFRII activation mainly increased the fraction of CD25+ CD4+ Treg cells. In contrast, in CD8+ T cells, TNFRII activation elevated the percentage of FoxP3+ CD8+ Treg cells, implying different mechanisms of TNFRII-dependent expansion of CD4+ and CD8+ Treg cells. Due to the important role of CD25 for functional IL-2 signaling in Treg cells, the different TNFRII-dependent regulation of CD25 and FoxP3 might affect the responsiveness of CD4+ or CD8+ Treg cells for IL-2 signaling. Consistent with our data, a recent report showed that upon IL-2 activation, CD25 up-regulation was lower for CD8+ than for CD4+ Treg cells (46) . In contrast, we did not observe TNFRII-dependent changes in IL-2 signaling pathways (i.e., pSTAT-5, p70SK6, and pERK-1/2 levels). This is consistent with recent reports showing that TNFRII activation does not affect pSTAT-5 levels (17, 45) . Further studies are needed to clarify the molecular effects of TNFRII on CD4+ and CD8+ Treg cells.
The transcription factor FoxP3, a member of the forkhead/winged helix family and a unique marker specific for the Treg cell lineage, determines the phenotype and immunosuppressive function of CD4+ Treg cells. Similar to the expression of CD4+ Treg cells, expression of FoxP3 in CD8+ Treg cells has been described in both rodents and humans, and FoxP3 expression seems to determine the suppressive potential of CD8+ Treg cells (47) . It was previously shown that TNFRII plays a critical role in sustaining FoxP3 expression and, consequently, in maintaining the phenotypic and functional stability of CD4+ Treg cells (21) . We have shown herein that selective activation of TNFRII promotes the expansion of FoxP3+ cells, particularly in CD8+ Treg cells.
Since Treg cells control pathogenic self-reactive cells and maintain immunologic homeostasis, these T cell subsets hold great therapeutic potential for autoimmune diseases (38, 39) . Clinical trials exploring the therapeutic potential of Treg cells in human immune-mediated diseases have begun using expanded autologous CD4+ CD25+FoxP3+ Treg cells isolated from the blood (48) . However, Treg cells are difficult to expand from the small numbers that can be isolated, and their functional properties decrease after large expansion (49 (26) showed that anti-CD3 therapy expands both CD4+ and CD8+ Treg cells and induces sustained amelioration of experimental arthritis. Consistent with this, we report herein that treatment of mice with the TNFRII agonist EHD2-sc-mTNF R2 was therapeutic in the CIA model. After application of the TNFRII agonist, the proportion of both CD4+ and CD8+ Treg cells was increased, and elevated levels of the cytokine IL-10 were found in the circulating blood, indicating antiinflammatory responses induced by EHD2-sc-mTNF R2 .
These antiinflammatory responses in the peripheral immune system correlate with reduced inflammation in the joints (i.e., reduced infiltration of T cells and macrophages). IL-10 is a key antiinflammatory cytokine that can be secreted by both M2-polarized macrophages and Treg cells. Both M2-polarized macrophages and Treg cells have been associated with arthritis recovery (50, 51) . While we cannot exclude a contribution of macrophages to the therapeutic effect of EHD2-sc-mTNF R2 , a recent study showed that TNFRII signaling in Treg cells induces secretion of IL-10 (45), indicating a therapeutic role of Treg cells.
It was previously shown that expansion of CD8+ Treg cells strongly inhibited CIA development and infusion of in vitro-expanded CD8+ Treg cells increased the efficacy of methotrexate treatment and halted disease progression after clinical onset (25) . Importantly, Treg cells needed to be expanded prior to development of arthritic symptoms to achieve therapeutic responses. This is consistent with our data, showing that under the 2-armed (early/ late) treatment protocol we used, therapeutic activity could only be recorded when the TNFRII agonist was given before the visible onset of arthritis. However, one should consider that disease development in the CIA model is very strong and does not represent the development and progression of RA in humans who are treated early. Furthermore, in humans, the development of arthritis is often preceded by other symptoms, such as pain. This might be an important indicator time point for the potential start of treatment with drugs that affect Treg cells, such as TNFRII agonists. Furthermore, in naive mice, Treg cell expansion after TNFRII agonist application was dosedependent; therefore, it is possible that a higher dose or more frequent dosing of the TNFRII agonist is therapeutic in CIA.
In another study, progression of CIA was suppressed by either inhibiting TNFRI or by completely blocking TNFRI and TNFRII. Interestingly, selective inhibition of TNFRI, but not complete blockade of TNFRI and TNFRII, was shown to expand and activate Treg cells (15) , indicating that TNFRII is necessary for the maintenance of immunosuppressive signaling. This is consistent with a recent study showing that anti-CD3-dependent CD8+ Treg cell induction in blood from RA patients is supported by tmTNF, the prime activating ligand of TNFRII, which is expressed on monocytes (52) . Results from recent anti-CD3 therapy trials have been less encouraging, however, since they failed to achieve their primary clinical end point, which was partly due to marked variation in response (53) . Other, more selective therapies, such as TNFRII agonists, therefore hold greater potential.
In summary, we provide evidence that selective TNFRII activation expands not only CD4+ Treg cells, but also CD8+ Treg cells in vivo and that the increase in both Treg subpopulations induced by the TNFRII agonist is correlated with therapeutic responses in experimental arthritis. Our results suggest that the development of therapeutic strategies based on the TNFRII-dependent specific in vivo expansion of CD4+ and/or CD8+ Treg cells may represent a new and effective approach to the treatment of various autoimmune diseases.
